Michael H. Ossipov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael H. Ossipov has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Ad (Bud) Craig
1 shared publication- Allan I. Basbaum
Department of Anatomy, University of California, San Francisco, San Francisco, USA
1 shared publication - Andrew Dickman
Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
1 shared publication - Andrew J. Todd
School of Psychology and Neuroscience, Sir James Black Building, University of Glasgow, Glasgow, G12 8QQ, UK
1 shared publication - Andrew Moore
Lancaster University, Lancaster, LA1 4YW United Kingdom
1 shared publication - Andrew Sc Rice
Pain Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom
1 shared publication
Latest Publications
- 1 January 2020
- Published by Portico in Drugs of Today
- Vol. 56 (1) , 5-19
Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache
Migraine is a common, painful and highly disabling neurological condition that has plagued mankind for millennia, but its pathophysiology remained largely obscure until recently. The clinical success of triptans for treating migraine and the discovery that calcitonin gene-related peptide (CGRP) plays a prominent role in migraine led to increased research interest into this disease. An important improvement has been the development of monoclonal antibodies, including galcanezumab, that bind to CGRP or to its receptor, preventing its activation. Subsequent clinical trials have reported that galcanezumab is safe and well tolerated, and is effective in reducing the frequency of migraine attacks in patients with episodic or chronic migraine. At the same time, increased study of the pathophysiology of cluster headache, a relatively rare condition with excruciatingly painful headache attacks (i.e., "suicide headaches"), led to the discovery that, as in migraine, CGRP plays an important role in its pathology. Clinical trials suggest that galcanezumab is safe and effective for the prevention of episodic cluster headache, and it is under study for chronic cluster headache. Galcanezumab is approved for the prevention of migraine in the U.S., the European Union, Canada and Mexico, and was also approved for the treatment of episodic cluster headache in the U.S.
- 1 January 2020
- Published by Portico in Drugs of Today
- Vol. 56 (1) , 5-19
Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache
Migraine is a common, painful and highly disabling neurological condition that has plagued mankind for millennia, but its pathophysiology remained largely obscure until recently. The clinical success of triptans for treating migraine and the discovery that calcitonin gene-related peptide (CGRP) plays a prominent role in migraine led to increased research interest into this disease. An important improvement has been the development of monoclonal antibodies, including galcanezumab, that bind to CGRP or to its receptor, preventing its activation. Subsequent clinical trials have reported that galcanezumab is safe and well tolerated, and is effective in reducing the frequency of migraine attacks in patients with episodic or chronic migraine. At the same time, increased study of the pathophysiology of cluster headache, a relatively rare condition with excruciatingly painful headache attacks (i.e., "suicide headaches"), led to the discovery that, as in migraine, CGRP plays an important role in its pathology. Clinical trials suggest that galcanezumab is safe and effective for the prevention of episodic cluster headache, and it is under study for chronic cluster headache. Galcanezumab is approved for the prevention of migraine in the U.S., the European Union, Canada and Mexico, and was also approved for the treatment of episodic cluster headache in the U.S.
- Open Access
- 25 August 2018
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 44 (1) , 125-128
Discovery of “folded DNA” structures in human cells: Potential drug targets
What is known and objective The double‐helical conformation of human DNA (hDNA) is so axiomatic that it is called the “canonical” form. Recently, though, intrastrand folds (“I‐motifs” and “G‐quadruplexes”) have been identified in hDNA. These could be targets for novel drug discovery. Comment Any interruption of the canonical form of hDNA fundamentally impacts the normal progression of transduction and translation. In particular, the synthesis of receptors and cognate protein ligands would be affected, as well as their affinity for—and signal transduction of—pharmacotherapeutic agents. Recent studies have identified normally occurring, folded structures superimposed on the usual double‐helix motif of hDNA. What is new and conclusion The newly identified “folded DNA” structures (“I‐motifs” and “G‐quadruplexes”) could represent novel drug‐discovery targets, most likely for cancer.
- 25 August 2018
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 44 (1) , 125-128
Open AccessDiscovery of “folded DNA” structures in human cells: Potential drug targets
What is known and objective The double‐helical conformation of human DNA (hDNA) is so axiomatic that it is called the “canonical” form. Recently, though, intrastrand folds (“I‐motifs” and “G‐quadruplexes”) have been identified in hDNA. These could be targets for novel drug discovery. Comment Any interruption of the canonical form of hDNA fundamentally impacts the normal progression of transduction and translation. In particular, the synthesis of receptors and cognate protein ligands would be affected, as well as their affinity for—and signal transduction of—pharmacotherapeutic agents. Recent studies have identified normally occurring, folded structures superimposed on the usual double‐helix motif of hDNA. What is new and conclusion The newly identified “folded DNA” structures (“I‐motifs” and “G‐quadruplexes”) could represent novel drug‐discovery targets, most likely for cancer.
- 17 March 2016
- Published by Taylor & Francis in Pain Management
- Vol. 6 (2) , 111-120
Cortical and Subcortical Modulation of Pain
Pain is more than merely nociception and response, but rather it encompasses emotional, behavioral and cognitive components that make up the pain experience. With the recent advances in imaging techniques, we now understand that nociceptive inputs can result in the activation of complex interactions among central sites, including cortical regions that are active in cognitive, emotional and reward functions. These sites can have a bimodal influence on the serotonergic and noradrenergic descending pain modulatory systems via communications among the periaqueductal gray, rostral ventromedial medulla and pontine noradrenergic nuclei, ultimately either facilitating or inhibiting further nociceptive inputs. Understanding these systems can help explain the emotional and cognitive influences on pain perception and placebo/nocebo effects, and can help guide development of better pain therapeutics.
- 17 March 2016
- Published by Taylor & Francis in Pain Management
- Vol. 6 (2) , 111-120
Cortical and Subcortical Modulation of Pain
Pain is more than merely nociception and response, but rather it encompasses emotional, behavioral and cognitive components that make up the pain experience. With the recent advances in imaging techniques, we now understand that nociceptive inputs can result in the activation of complex interactions among central sites, including cortical regions that are active in cognitive, emotional and reward functions. These sites can have a bimodal influence on the serotonergic and noradrenergic descending pain modulatory systems via communications among the periaqueductal gray, rostral ventromedial medulla and pontine noradrenergic nuclei, ultimately either facilitating or inhibiting further nociceptive inputs. Understanding these systems can help explain the emotional and cognitive influences on pain perception and placebo/nocebo effects, and can help guide development of better pain therapeutics.
- Open Access
- 1 January 2012
- Published by Wiley in Scientifica
- Vol. 2012, 1-25
The Perception and Endogenous Modulation of Pain
Pain is often perceived an unpleasant experience that includes sensory and emotional/motivational responses. Accordingly, pain serves as a powerful teaching signal enabling an organism to avoid injury, and is critical to survival. However, maladaptive pain, such as neuropathic or idiopathic pain, serves no survival function. Genomic studies of individuals with congenital insensitivity to pain or paroxysmal pain syndromes considerable increased our understanding of the function of peripheral nociceptors, and especially of the roles of voltage-gated sodium channels and of nerve growth factor (NGF)/TrkA receptors in nociceptive transduction and transmission. Brain imaging studies revealed a “pain matrix,” consisting of cortical and subcortical regions that respond to noxious inputs and can positively or negatively modulate pain through activation of descending pain modulatory systems. Projections from the periaqueductal grey (PAG) and the rostroventromedial medulla (RVM) to the trigeminal and spinal dorsal horns can inhibit or promote further nociceptive inputs. The “pain matrix” can explain such varied phenomena as stress-induced analgesia, placebo effect and the role of expectation on pain perception. Disruptions in these systems may account for the existence idiopathic pan states such as fibromyalgia. Increased understanding of pain modulatory systems will lead to development of more effective therapeutics for chronic pain.
- 1 January 2012
- Published by Wiley in Scientifica
- Vol. 2012, 1-25
Open AccessThe Perception and Endogenous Modulation of Pain
Pain is often perceived an unpleasant experience that includes sensory and emotional/motivational responses. Accordingly, pain serves as a powerful teaching signal enabling an organism to avoid injury, and is critical to survival. However, maladaptive pain, such as neuropathic or idiopathic pain, serves no survival function. Genomic studies of individuals with congenital insensitivity to pain or paroxysmal pain syndromes considerable increased our understanding of the function of peripheral nociceptors, and especially of the roles of voltage-gated sodium channels and of nerve growth factor (NGF)/TrkA receptors in nociceptive transduction and transmission. Brain imaging studies revealed a “pain matrix,” consisting of cortical and subcortical regions that respond to noxious inputs and can positively or negatively modulate pain through activation of descending pain modulatory systems. Projections from the periaqueductal grey (PAG) and the rostroventromedial medulla (RVM) to the trigeminal and spinal dorsal horns can inhibit or promote further nociceptive inputs. The “pain matrix” can explain such varied phenomena as stress-induced analgesia, placebo effect and the role of expectation on pain perception. Disruptions in these systems may account for the existence idiopathic pan states such as fibromyalgia. Increased understanding of pain modulatory systems will lead to development of more effective therapeutics for chronic pain.
- 16 February 2011
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 15 (3) , 185-192
Growth Factors and Neuropathic Pain
A treatment for neuropathic pain is an important unmet medical need because this pain often is refractory to many medical interventions. An important element in the development of neuropathic pain is a dysfunction in the activity of peripheral nerves. Because neurotrophic factors affect nerve development and maintenance, modulating the activity of these factors can alter neuronal pathophysiology and produce a disease-modifying effect. Blocking the activity of nerve growth factor or enhancing the activity of either glial-derived neurotrophic factor or artemin has shown potential for normalizing neuronal activity and attenuating signs of neuropathic pain in animal models and clinical studies. This article discusses the role of these factors in neuropathic pain and the implications for the development of novel therapeutics.
- 16 February 2011
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 15 (3) , 185-192
Growth Factors and Neuropathic Pain
A treatment for neuropathic pain is an important unmet medical need because this pain often is refractory to many medical interventions. An important element in the development of neuropathic pain is a dysfunction in the activity of peripheral nerves. Because neurotrophic factors affect nerve development and maintenance, modulating the activity of these factors can alter neuronal pathophysiology and produce a disease-modifying effect. Blocking the activity of nerve growth factor or enhancing the activity of either glial-derived neurotrophic factor or artemin has shown potential for normalizing neuronal activity and attenuating signs of neuropathic pain in animal models and clinical studies. This article discusses the role of these factors in neuropathic pain and the implications for the development of novel therapeutics.
- 1 January 2006
- Published by Elsevier
Contributors